Overview

This trial is active, not recruiting.

Condition age-related macular degeneration
Treatment cd 35, cd21, cd55
Sponsor Rudolf Foundation Clinic
Start date September 2008
End date December 2009
Trial size 120 participants
Trial identifier NCT01174407, EK08010-VK

Summary

The purpose of this study is to determine a possible implication of CD21, CD35 and CD55 in the pathogenesis of age-related macular degeneration. The aim is to asses a difference in expression rates of these factors on AMD-patients and a healthy control group.

United States No locations recruiting
Other Countries No locations recruiting

Study Design

Observational model case control
Time perspective prospective
Arm
cd 35, cd21, cd55
Blood drawing/ 10ml/ once- duration of 1 day of full examination of the patient

Primary Outcomes

Measure
determine a possible implication of CD21, CD35 and CD55 in the pathogenesis of age-related macular degeneration
time frame: 1 day

Secondary Outcomes

Measure
expression rates of on AMD-patients and a healthy control group
time frame: 1 year

Eligibility Criteria

Male or female participants at least 55 years old.

Inclusion Criteria: - Man and women over 18 years old - Filled out informed consent - Diagnosis of non-exudative/ exudative age related macular degeneneration Exclusion Criteria: - Inherited retinal diseases - Other acquired retinal/ macular - Missing informed consent

Additional Information

Official title Is CD35, CD21 and CD55 Associated With Exudative Age-related Macular Degeneration
Trial information was received from ClinicalTrials.gov and was last updated in August 2010.
Information provided to ClinicalTrials.gov by Rudolf Foundation Clinic.